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pital admission in the next year but paradoxically it also
increased the probability of having zero hospital costs due
to increased risk of death without hospitalization.
CONCLUSIONS: Costs incurred in previous years can be
used to predict costs and outcomes in the future. This dy-
namic three-part model clarifies the relationship between
risk of hospitalization, cost of hospitalization and mortality.
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OBJECTIVE: To establish the likely health and cost im-
pacts of a pre-school booster vaccination for Bordetella
pertussis, when added to existing UK primary vaccina-
tion schedules assuming that a diphtheria, tetanus, and
acellular pertussis, (DTPa) booster would replace the cur-
rent diphtheria and tetanus (DT) booster.
METHODS: A transition state model of pertussis infec-
tion in a closed population representative of England and
Wales, comprised of eight age bands with susceptible, in-
fected and immune population sub-groups. Herd-immu-
nity was explicitly modeled. Epidemiological service use
and cost data were sourced from routine statistics, pub-
lished literature and, where necessary, clinical estimates.
The number of pertussis cases, hospitalizations and
deaths were forecast for a five-year period. Quality of life
gains were not explicitly calculated.
RESULTS: Introducing a pre-school pertussis booster
and achieving 84% coverage is predicted to cost an addi-
tional £14.32m over a five-year period, assuming £5
marginal cost between DTPa and DTP or £8.60m assum-
ing a £3 marginal cost. Offset against this are the cost of
reduced hospitalizations and GP consultations, which are
expected to total between £4.21m and £4.60m. The re-
turn on this investment would be a reduction in up to
1700 hospitalizations, between 5000 and 27,000 pertus-
sis cases depending on the level of under-reporting and
assuming a vaccine waning period, and one infant death.
CONCLUSIONS: The introduction of a pre-school
booster is predicted to significantly reduce the number of
hospitalizations and pertussis cases contracted. The esti-
mated marginal cost of this strategy is £10m over a five-
year period, assuming a £5 difference between DTP and
DTPa or £4m, were the difference only £3.
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Viral respiratory infection (VRI) is the most commonly oc-
curring illness in man, imposing considerable burden on
patients and on society. However, to date, no formal study
of the economic impact of VRI has been performed.
OBJECTIVES: To rigorously quantify the economic im-
pact of viral respiratory disease (VRI) in the US in terms
of health-care resource utilization (direct costs) and pro-
ductivity losses (indirect costs).
METHODS: Publicly available databases including the
US Census, National Health Interview Survey (NHIS),
the Medical Expenditure Panel Survey (MEPS) and the
National Ambulatory Medical Care Survey (NAMCS)
were used. From these databases, projections regarding
population characteristics, physician and emergency-room
encounters, prescription and over-the-counter drug utiliza-
tion, and productivity losses related to VRI were made.
Data obtained from primary epidemiological research and
prospective randomized clinical trials were used to esti-
mate the incidence of VRI in the general population and
the rate of secondary clinical complications associated
with VRI.
RESULTS: Nearly 500 million episodes of VRI occur an-
nually in the US alone. Direct costs associated with VRI
are estimated to be $16.8 billion annually and are broken
down as follows: physician visits, $6 billion; complica-
tions, $3.8 billion; prescription and over-the-counter medi-
cations, $4.8 billion. Indirect costs for employed individu-
als approximate $7.6 billion per year. Physician encounters
via a telephone and the internet, productivity losses incurred
by caregivers (i.e. parent) of VRI-infected individuals, and
costs associated with diminished productivity while at work
or home were not included, suggesting that this projection
of total VRI costs—$25 billion annually in the US alone—is
very likely an under-estimate.
CONCLUSIONS: Viral respiratory infections impose a
significant clinical and economic burden to society, ap-
proaching or surpassing the aggregate costs of many
common chronic diseases. The resultant clinical and cost
ramifications attributable to this common acute condi-
tion warrants increased attention from health-care pro-
viders and policy makers.
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OBJECTIVE: Pneumococcal conjugate vaccine for in-
fants has recently been found effective against meningitis,
